Business Wire·Nov 10, 2026, 4:05 PM ET

Atara Biotherapeutics Announces Third Quarter 2026 Financial Results and Operational Progress

ATRA

Atara Biotherapeutics reported financial results for the third quarter of 2026 with a PDUFA target action date of March 31, 2027, for its tab-cel BLA resubmission.
FDA acceptance of the BLA resubmission for tabelecleucel covers adult and pediatric patients aged two and older with EBV+ PTLD who have received prior therapy.
Approval of the BLA would trigger a $31 million milestone payment from Pierre Fabre Laboratories & eligibility for double-digit tiered royalties.
The company achieved a nine-month year-over-year reduction in costs & operating expenses of approximately 83%.
Cash, cash equivalents, & short-term investments totaled $9.9 million as of September 30, 2026.
Net cash used in operating activities was $0.9 million for the third quarter 2026, down from $9.8 million in the same period of 2025.
Total revenues for the third quarter 2026 were $1.2 million, a decrease of $2.3 million year-over-year primarily due to a one-time clinical inventory sale in the prior year.
Research & development expenses were $1.1 million for the third quarter 2026 compared to $2.9 million in the prior year period.
General & administrative expenses were $2.8 million for the third quarter 2026 compared to $4.0 million in the prior year period.
Atara reported a net loss of $2.2 million, or ($0.15) per share, for the third quarter 2026, compared to a net loss of $4.3 million, or ($0.32) per share, in 2025.
The company expects its cash resources & operating efficiencies to fund planned operations into mid-2027.